D. Boral Capital downgraded FibroBiologics (FBLG) to Hold from Buy and no price target following the announcement of a 1-for-20 reverse stock split. Reverse splits “are typically associated with prolonged pressure on investor sentiment and liquidity, warranting a more cautious near-term stance,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics announces 1-for-20 reverse stock split
- FibroBiologics: CYWC628 Drives Buy Rating on Strong Preclinical Wound and Burn Data in Large Underserved Markets
- FibroBiologics announces expansion of wound care platform
- FibroBiologics Updates CFO Compensation to Support Leadership
- FibroBiologics completes site onboarding for Phase 1/2 trial of CYWC628